Literature DB >> 6420100

Pathogenesis of rheumatoid arthritis.

E D Harris.   

Abstract

Rheumatoid arthritis (RA) is initiated by an unknown antigen(s) in the genetically programmed host. HLA-DR4 is associated with RA. The antigen could be exogenous (e.g., Epstein-Barr virus, bacterial cell wall products) or endogenous (e.g., collagen or immunoglobulin). Within the synovium, where the immune response begins, monocytes and lymphocytes are activated. Polyclonal B-cell proliferation results, as well as production of monokines and lymphokines. The antibodies form immune complexes with other antibody molecules or antigens. Phagocytosis of immune complexes results in production of many autacoids and activation of other soluble mediator systems, e.g., the coagulation, kinin, complement, and fibrinolytic systems in synovial fluid. Chemotactic factors draw polymorphonuclear leukocytes into the joint space. Monokines stimulate synovial cell proliferation; these cells, in turn, synthesize proteinases and products of arachidonate metabolism capable of destroying normal articular structures.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6420100

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  5 in total

1.  Treatment perspectives in rheumatoid arthritis: a descriptive study in a Swedish healthcare district.

Authors:  P Bendtsen; P Bjurulf; E Trell; F Lindström; J E Larsson
Journal:  Pharmacoeconomics       Date:  1994-05       Impact factor: 4.981

Review 2.  Dendritic cells in the pathogenesis of rheumatoid arthritis.

Authors:  L M March
Journal:  Rheumatol Int       Date:  1987       Impact factor: 2.631

3.  Update on treatment of rheumatoid arthritis.

Authors:  A C Patterson
Journal:  Can Fam Physician       Date:  1987-03       Impact factor: 3.275

Review 4.  Cellular basis and oncogene expression of rheumatoid joint destruction.

Authors:  S Gay; R E Gay
Journal:  Rheumatol Int       Date:  1989       Impact factor: 2.631

5.  Effect of etodolac, a new nonsteroidal anti-inflammatory drug, in MRL/lpr mice with articular lesions.

Authors:  H Yoshida-Suzuka; Y Nakamura; Y Shibata; K Kimura
Journal:  Agents Actions       Date:  1991-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.